{
    "name": "tixagevimab and cilgavimab",
    "comment": "Investigational",
    "other_names": [
        "Evusheld"
    ],
    "classes": [
        "Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/evusheld-tixagevimab-cilgavimab-4000251",
    "pregnancy": {
        "common": [
            "Data are insufficient to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Nonclinical reproductive toxicity studies have not been conducted with tixagevimab and cilgavimab; in a tissue cross-reactivity study assessing off-target binding of tixagevimab and cilgavimab to human fetal tissues, no binding of clinical concern was observed",
            "Human IgG1 antibodies are known to cross the placental barrier; therefore, tixagevimab and cilgavimab have the potential to be transferred from the mother to the developing fetus; unknown whether the potential transfer of tixagevimab and cilgavimab provides any treatment benefit or risk to the developing fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are unavailable regarding presence in human milk or animal milk, effects on breastfed infants, or effects on milk production",
            "Maternal IgG is known to be present in human milk",
            "Consider developmental and health benefits of breastfeeding, along with the motherâ€™s clinical need for treatment and any potential adverse effects on the breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Severe hypersensitivity reactions, including anaphylaxis, to tixagevimab, cilgavimab, or any of their components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious hypersensitivity reactions, including anaphylaxis, reported with human immunoglobulin G1 (IgG1) monoclonal antibodies; if observed, immediately discontinue administration, and initiate appropriate medications and/or supportive care",
                "Caution when administering IM injections to individuals with thrombocytopenia or any coagulation disorder"
            ],
            "specific": [
                {
                    "type": "Cross-hypersensitivity with COVID-19 vaccines",
                    "description": [
                        "Contains polysorbate 80, which is in some COVID-19 vaccines and is structurally like polyethylene glycol (PEG), an ingredient in other COVID-19 vaccines",
                        "Consider consulting an allergist/immunologist before administering to individuals with a history of severe hypersensitivity reactions to a COVID-19 vaccine ",
                        "Administer under supervision of healthcare provider with appropriate medical support to manage severe hypersensitivity reactions",
                        "Immediately discontinue administration if signs and symptoms of clinically significant hypersensitivity reaction or anaphylaxis occur and initiate appropriate medications and/or supportive care ",
                        "Clinically monitor and observe for at least 1 hr "
                    ]
                },
                {
                    "type": "Cardiovascular events",
                    "description": [
                        "In the clinical trial, there was a higher rate of cardiovascular serious adverse events (SAEs), including myocardial infarction (1 fatal SAE) and cardiac failure, in patients who received tixagevimab and cilgavimab ",
                        "All who experienced cardiac SAEs had cardiac risk factors and/or history of cardiovascular disease, and there was no clear temporal pattern",
                        "Causal relationship between tixagevimab and cilgavimab and these events has not been established",
                        "There was no signal for cardiac toxicity or thrombotic events identified in the nonclinical studies"
                    ]
                },
                {
                    "type": "Viral variants",
                    "description": [
                        "Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies",
                        "Prescribing clinicians should consider prevalence of resistant variants in their area",
                        "Health care providers should review antiviral resistance information provided by state and local health departments",
                        "October 3, 2022: Tixagevimab/cilgavimab showed no significant reduction in susceptibility to the alpha, beta, gamma, delta, epsilon, or iota, kappa, lambda, mu, or zeta variants ",
                        "November 10, 2022 NIH statement on omicron subvariants ",
                        "Subvariants BA.4.6, BA.2.75.2, BA.5.2.6, BF.7, BQ.1, and BQ.1.1 are likely to be resistant to tixagevimab/cilgavimab ",
                        "NIH Guidelines Panel",
                        " recommends that in the absence of an alternative option for PrEP, clinicians should continue to recommend tixagevimab/cilgavimab as PrEP for eligible individuals ",
                        "Omicron and omicron subvariants",
                        "October 3, 2022: omicron and omicron subvariants showed varying degrees of reduced susceptibility  ",
                        "BA.1: 132- to 183-fold reduction (pseudotyped VLPs); 12- to 30-fold reduction (authentic virus) ",
                        "BA.1.1: 424-fold reduction (pseudotyped VLPs); 176-fold reduction (authentic virus) ",
                        "BA.2: No change (pseudotyped VLPs); 5.4-fold reduction (authentic virus) ",
                        "BA.2.12.1: 5-fold reduction (pseudotyped VLPs)",
                        "BA.2.7.5: 2.4- to 15-fold reduction (pseudotyped VLPs); - to -fold reduction (authentic virus) ",
                        "BA.3: 16-fold reduction (pseudotyped VLPs)",
                        "BA.4: 33- to 65-fold reduction (pseudotyped VLPs)",
                        "BA.4.6: >1,000-fold reduction (pseudotyped VLPs)  ",
                        "BA.5: 33- to 65-fold reduction (pseudotyped VLPs); 2.8- to 16-fold reduction (authentic virus)  ",
                        "Variant proportions circulating in the US can be monitored at the ",
                        "CDC website"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "SAEs related to coronary artery disease or myocardial ischemia",
            "percent": "0.3"
        },
        {
            "name": "Myocardial infarctions",
            "percent": "0.2"
        },
        {
            "name": "SAEs related to cardiac failure",
            "percent": "0.2"
        },
        {
            "name": "SAEs related to arrhythmias",
            "percent": "0.1"
        },
        {
            "name": "Cardiomegaly",
            "percent": "0.1"
        },
        {
            "name": "cardiomyopathy",
            "percent": null
        },
        {
            "name": "cardiorespiratory arrest",
            "percent": null
        }
    ]
}